Iterum Therapeutics plc (NASDAQ:ITRM) Sees Large Decline in Short Interest

Iterum Therapeutics plc (NASDAQ:ITRM) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 1,790,000 shares, a decrease of 20.8% from the December 31st total of 2,260,000 shares. Based on an average daily volume of 2,880,000 shares, the short-interest ratio is currently 0.6 days. Approximately 6.7% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ITRM. XTX Topco Ltd bought a new stake in Iterum Therapeutics during the third quarter worth approximately $36,000. Apollon Financial LLC lifted its stake in shares of Iterum Therapeutics by 11.3% in the fourth quarter. Apollon Financial LLC now owns 250,250 shares of the company’s stock worth $443,000 after buying an additional 25,500 shares during the last quarter. Finally, Lee Financial Co bought a new stake in shares of Iterum Therapeutics during the 4th quarter worth $28,000. Institutional investors and hedge funds own 9.21% of the company’s stock.

Iterum Therapeutics Trading Up 4.7 %

Iterum Therapeutics stock traded up $0.07 during mid-day trading on Thursday, hitting $1.57. 662,886 shares of the company’s stock were exchanged, compared to its average volume of 551,481. Iterum Therapeutics has a 1-year low of $0.81 and a 1-year high of $3.02. The stock has a 50 day moving average of $1.86 and a two-hundred day moving average of $1.43. The stock has a market cap of $43.20 million, a P/E ratio of -0.79 and a beta of 2.33.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.